2023
The CARMA Global study, part of the EPIICAL project, has successfully met its recruitment target and recruited 99 children and adolescents living with HIV from across the globe. The study includes children and adolescents who acquired HIV around the period of their birth and then started antiretroviral therapy (ART) at a young age to control the virus and prevent its progression.
The primary aim of CARMA Global is to investigate how the body responds to HIV and how the virus is stored and behaves in the body over time.
2023
Authors: Abdalla S, Compagnucci A, Riault Y, Chan KM, Bamford A, Nolan A, Ramos TJ, Constant V, Nguyen T, Zheng Y, Tréluyer J, Froelicher-Bournaud L, Neveux N, Saidi Y, Cressey RT, Hirt D on behalf of the SMILE study group
Published in: Antimicrobial Agents and Chemotherapy
2023
In recent years, advancements in medical research have paved the way for an array of treatment options for children living with HIV. The efforts of scientists and researchers globally, have led to continuous refinement and improvement of existing regimens. Dr. Vivian Mumbiro, affectionately known as Dr V, a dedicated Medical Officer at the University of Zimbabwe Clinical Research Centre, shares insights into the evolving landscape of paediatric HIV treatment.
2023
In the quest to enhance our understanding of paediatric HIV and improve treatment outcomes, the EPIICAL project has worked tirelessly for the past eight years to gather and generate knowledge on HIV in children. Established with the ambitious goal of creating models to predict how children’s bodies respond to early antiretroviral therapy (ART) and treatment interruption, the EPIICAL project has also aimed to refine methods for understanding immune,
2023
Authors: Soeorg H, Padari H, Ilmoja M-L, Herodes K, Kipper K, Lutsar I, Metsvaht T, NeoMero Consortium
Published in: British Journal of Clinical Pharmacology
2023
Authors: Schröter J & De Boer R
Published in: Journal of Theoretical Biology 2023
2023
Authors: Barlow-Mosha L.N., Ahimbisibwe G.M., Chappell E., Amuge P.M., Nanduudu A., Kaudha E., Amukele T., Balamusani D., Kafufu B., Nimwesiga A., Kataike H., Namwanje R., Kasangaki G., Mulindwa A., Muzorah, G.A., Bbuye D., Musiime V., Mujyambere E., Ssenyonga M., Mulima D., Kyambadde R.C., Namusanje J., Isabirye R., Nabalamba M., Nakirya B.M., Kityo C., Kekitiinwa A.R., Giaquinto, C., Copp A., Gibb, D.M., Ford, D., Musoke P., Turkova A
Published in: Journal of the International AIDS Society
2023
Authors: Bevers LAH., Kamphuis AEM., van der Wekken-Pas LC, Leisegang R, Lewis L, Burger DM, Colbers A
Presented at: International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023
2023
The D3 trial is excited to announce that it has successfully completed recruitment in the trial at an exceptional speed. D3 is looking to see if a new tablet, a combination of two anti-HIV medicines, dolutegravir (DTG) and lamivudine (3TC), is as good and effective in treating HIV in children and young people living with HIV in comparison to the current paediatric anti-HIV medicines available.
The trial recruited 370 children from South Africa,
2023
FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF). The second aims to develop investigational pediatric formulations of TAF and sofosbuvir (SOF) designed to eliminate bitterness.
For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment,
2023
Between the months of April and May 2023, Penta hosted advisory group meetings where young people between the ages of 15 and 19 from South Africa, Argentina, the United Kingdom and Thailand, were invited to share their experiences and knowledge of long-acting injectable antiretrovirals at local in-person consultation workshops. The young people all had recent experience in paediatric HIV care and joined in the discussions about the acceptability, challenges and solutions of adopting and using long-acting injectables for themselves and their peers and how this could support or impact their transition to adult care.
2023
Findings from the Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (PENTA-17) trial, simply known as SMILE, were published in eClinicalMedicine on 2 June 2023. SMILE is the first randomised trial to determine whether children living with HIV on ART with suppressed viral load could maintain the suppression on a once-daily regimen compared to the standard of care (SOC) which involves three ART drugs.
2023
The inaugural Clinical Trial Management training program took place online on Wednesday, 14 June 2023, after 428 participants registered. The session was well attended by up to 168 clinical trial staff representing 30 countries. The training course is being implemented by UNIVERSAL’s Work package 8 and focuses on improving the capacity of research staff and young investigators to design, implement, and manage regulatory clinical trials, especially paediatric clinical trials.
This was the first module,
2022
2022
The EPIICAL General Assembly was held online and in person in Venice on 2-4 November 2022. It brought together 80 participants from 29 organisations from the EPIICAL consortium. Attendees came together to discuss, among other topics, highlights of the project as a clinical and experimental platform to evaluate therapeutic strategies for HIV remission and/or cure in children, updates in the treatment and management of paediatric HIV and the vision for EPIICAL in 2024 and beyond.
2022
Authors: Burke, T; Conway, M
Presented at: AIDS 2022 an the International Workshop on HIV & Adolescence 2022